The outlook of companies tied to the drug's legacy presents a complex investment scenario . While the initial surge generated substantial profits , generic copies have significantly eroded sales . Investing in connected pharmaceutical companies now requires a discerning assessment of proprietary safeguards, evolving medical changes, and the potenti